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Abstract: Oxidative stress has been implicated in the pathogenesis and progression of COPD. 
Both reactive oxidant species from inhaled cigarette smoke and those endogenously formed by 
inﬂ  ammatory cells constitute an increased intrapulmonary oxidant burden. Structural changes 
to essential components of the lung are caused by oxidative stress, contributing to irreversible 
damage of both parenchyma and airway walls. The antioxidant N-acetylcysteine (NAC), a 
glutathione precursor, has been applied in these patients to reduce symptoms, exacerbations, 
and the accelerated lung function decline. This article reviews the available experimental and 
clinical data on the antioxidative effects of NAC in COPD, with emphasis on the role of exhaled 
biomarkers.
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Introduction
Inﬂ  ammation and oxidative stress play an important role in the pathogenesis of many 
chronic inﬂ  ammatory lung disorders such as COPD, asthma, bronchiectasis, and 
cystic ﬁ  brosis (CF). A complex interplay between the speciﬁ  c cause of the disease, 
host characteristics, and the type and intensity of inﬂ  ammation and oxidative stress 
results in the clinical picture and likelihood of progression of that speciﬁ  c disease. 
Noninvasively obtained biomarkers of inﬂ  ammation and oxidative stress have been 
identiﬁ  ed, and, ideally, should represent the intensity of the ongoing pathological 
processes within the lungs. This review focuses on the role of oxidative stress in the 
pathogenesis of COPD and the ability of N-acetylcysteine (NAC) to attenuate this 
process. Speciﬁ  c attention is paid to the role of biomarkers that follow the course of 
the disease and the effect of antioxidant interventions.
Oxidants and antioxidants in the lungs of patients 
with COPD
Several reviews have summarised the available data on the presence and consequences 
of oxidative stress in the lungs of “healthy” smokers and smokers with COPD (Repine 
et al 1997; MacNee and Rahman 1999; Rahman and MacNee 1999; Barnes 2000; 
MacNee 2000) (see Table 1). Cigarette smoke is a major source of oxidants in the 
lungs, eg, free radicals, nitric oxide (NO), semiquinone radicals, hydroxyl radicals, and 
hydrogen peroxide (H2O2) (MacNee and Rahman 1999). Furthermore, cigarette smoke 
promotes the inﬂ  ux and activation of neutrophils and macrophages. Leukocytes from 
smokers release more oxidants like superoxide anion (O2
–) and H2O2 than leukocytes 
from nonsmokers (Morrison et al 1999). The alveolar macrophages of smokers 
contain increased amounts of iron and release more free iron than those of nonsmokers 
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Mateos et al (1998). The presence of free iron facilitates the 
generation of very reactive hydroxyl radicals.
An important part of the pulmonary antioxidant defense 
is located in the epithelial lining ﬂ  uid (ELF). Vitamin C 
and vitamin E levels in ELF are depleted in smokers, but 
glutathione (GSH) levels are increased (Cantin et al 1987; 
Rahman and MacNee 1996; Morrison et al 1999). These 
effects depend on the time-course of exposure to tobacco 
smoke. Acute exposure markedly depletes antioxidants 
in plasma (Rahman et al 1996, 1997), intracellular 
GSH of erythocytes (Maranzana and Mehlhorn 1998), 
and GSH levels in ELF (Cantin et al 1987; Morrison 
et al 1999).
Alterations in the lung caused by 
oxidative stress
Both in vitro and in vivo experiments have demonstrated that 
oxidative stress may cause alterations in essential components 
of the lung, contributing to pathological abnormalities and 
functional changes (Table 2) (Rahman and MacNee 1996; 
Warren et al 1997).
Increased numbers of reactive oxygen species (ROS) 
have been shown to reduce the synthesis of elastin and 
collagen (Laurent et al 1983; Cantin and Crystal 1985). 
ROS may also affect the structure of components of the 
extracellular matrix, such as hyaluronate (Warren et al 
1997). Depolymerisation of the proteoglycans in the 
lung reduces the viscosity of the extracellular matrix. 
Oxidative stress may also initiate or amplify alterations 
in the airway wall. Lipid peroxidation may initiate the 
release of arachidonic acid from membrane phospholipids, 
in this way leading to release of prostaglandins and 
leukotrienes. Increased levels of ROS may also increase 
interleukin-1 (IL-1) and IL-8 production in several cell 
systems (Ghezzi et al 1991; Metinko et al 1992). Other 
effects include changes in protein structure leading to 
altered antigenicity and thus immune responses, contraction 
of smooth muscle, impairment of beta-adrenoceptor 
function, stimulation of airway secretion, pulmonary 
vascular smooth muscle relaxation or contraction, and 
activation of mast cells (Warren et al 1997). ROS may 
inactivate antiproteases such as alpha-1-proteinase 
inhibitor and secretory leukoprotease inhibitor (Abboud 
et al 1985). Changes in the alveolar epithelial cell layer 
occur both as a direct result of inhaled ROS and through 
the aforementioned alterations (Cotgreave and Moldeus 
1987). Sequestration of neutrophils may occur in the lung 
microcirculation, initiated by inhaled tobacco smoke 
(MacNee et al 1989). The increased and prolonged 
presence of these inﬂ  ammatory cells contributes to, for 
example, the cycle of locally increased ROS production 
and attraction of new inﬂ  ammatory cells. Finally, oxida-
tive stress activates the transcription factor nuclear factor 
kappa-beta (NF-kb), which switches on the genes for 
tumor necrosis factor-alpha (TNF-alpha), IL-8, and other 
inﬂ  ammatory proteins (Barnes 2000; Rahman and MacNee 
2000), in this way enhancing inﬂ  ammation.
Table 1 Indices of increased oxidative stress in COPD. 
Modiﬁ  ed after Rahman and MacNee (1999)
Biochemical marker
Elevated breath hydrogen peroxide and 8-isoprostane levels
Decreased plasma antioxidant capacity
Elevated plasma lipid peroxides (TBARs) levels
Plasma protein sulhydryl oxidation
Increased exhaled carbon monoxide
Release of ROS from peripheral blood neutrophils and alveolar 
macrophages
Increased urinary isoprostane F2-alpha-III levels
Abbreviations: TBARs, thiobarbituric acid-reactive substances.
Table 2 Alterations in components of the lung caused by 
oxidative stress. Modiﬁ  ed after Rahman and MacNee (1996), 
Warren et al (1997), and Dekhuijzen (2004)
Airway wall  Contraction of airway smooth muscle
  Impairment of Beta-adrenoceptor function
  Stimulation of airway secretion
  Pulmonary vascular smooth-muscle relaxa-
tion or contraction
  Activation of mast cells
Alveolar epithelial cell layer  > Permeability by detachment
 <  Adherence
 >  Cell lysis
Lung matrix  < Elastin synthesis and fragmentation
 <  Collagen synthesis and fragmentation
  Depolymerisation of proteoglycans
Antiproteases  Inactivation of alpha-1-proteinase inhibitor
  Inactivation of secretory leukoprotease 
inhibitor
Pulmonary microcirculation  > Permeability
 PMN  sequestration
 >  PMN adhesion to endothelium of arteri-
oles and venules
Transcription factors  Switch-on of genes for TNF-alpha, inter-
leukin-8, other inﬂ  ammatory proteins
Abbreviations: PMN, polymorphonuclear leukocyte; TNF-alpha, tumor necrosis 
factor-alpha.International Journal of COPD 2006:1(2) 101
NAC in COPD
Taken together, these data strongly suggest that oxidative 
stress is an important pathogenetic factor in the alterations in 
the lungs of patients with COPD. Attenuation of oxidative 
stress would be expected to result in reduced pulmonary dam-
age and a decrease of local infections, in this way contributing 
to attenuation of the progression of COPD. At present the 
only antioxidant widely available for the treatment in patients 
with COPD is NAC.
Antioxidant therapy with NAC in 
COPD
Antioxidant properties
NAC has direct and indirect antioxidant properties. Its free 
thiol group is capable of interacting with the electrophilic 
groups of ROS (Moldeus et al 1986; Aruoma et al 1989). 
This interaction with ROS leads to an intermediate formation 
of NAC thiol, with NAC disulﬁ  de as a major end product 
(Cotgreave 1997). NAC also exerts an indirect antioxidant 
effect related to its role as a GSH precursor. GSH is a 
tripeptide made up of glutamic acid, cysteine, and glycine. It 
serves as a central factor in protecting against internal toxic 
agents (such as cellular aerobic respiration and metabolism 
of phagocytes) and external agents (such as NO, sulfur oxide, 
and other components of cigarette smoke, and pollution). 
The sulfydryl group of cysteine neutralises these agents. In 
vitro, NAC acts as a precursor of GSH as it can penetrate 
cells easily and is subsequently deacylated to deliver cysteine 
(Moldeus et al 1986).
Clinical pharmacology
NAC is rapidly absorbed after oral administration (Sheffner 
et al 1966; Rodenstein et al 1978; Borgstrom et al 1986). 
Maximum plasma concentration after oral administration is 
reached after 2–3 hours (Bridgeman et al 1991) and plasma 
half-life is 6.3 hours. NAC undergoes extensive hepatic 
metabolism, resulting in a low bioavailability of about 
10% of the unchanged molecule. Cysteine and GSH levels 
are increased transiently in plasma (Cotgreave et al 1987; 
Bridgeman et al 1991) and lung (Bridgeman et al 1991) after 
oral administration of NAC 600 mg once daily. In patients 
with COPD, 600 mg three times daily increased plasma GSH 
levels (Bridgeman et al 1994). With this dose, administered 
for 5 days to patients who underwent lung resection surgery, 
cysteine and GSH levels were increased by ~50% compared 
with untreated patients. These data suggest that there is a 
transient dose-dependent effect of NAC on lung cysteine 
and GSH levels.
Antioxidant and anti-inﬂ  ammatory effects
The efﬁ  cacy of NAC as a precursor of GSH synthesis 
has been studied in isolated mouse lungs (Moldeus et al 
1986). Cigarette smoke administered directly to the lung 
through the trachea caused a dose-dependent reduction 
in total pulmonary GSH. Administering NAC together 
with cigarette smoke prevented the loss of pulmonary 
GSH and abolished the effects of cigarette smoke. NAC 
reduced H2O2-induced damage to epithelial cells in vitro 
(Cotgreave and Moldeus 1987) and NF-kb activation in 
some cells (Schreck et al 1992). In addition, NAC treat-
ment reduced cigarette smoke-induced abnormalities in 
polymorphonuclear leukocyte (PMN) (Bridges 1985), 
alveolar macrophages, ﬁ  broblasts, and epithelial cells in 
vitro (Moldeus et al 1985; Voisin 1987; Linden et al 1988; 
Drost et al 1991). Treatment with NAC also attenuated 
rat secretory cell hyperplasia induced by tobacco smoke 
(Jeffery et al 1985) and prevented hypochlorous acid 
(HOCl)-mediated inactivation of alpha-1-proteinase inhibi-
tor in vitro (Borregaard 1987). In a rat model of cigarette 
smoke-induced alterations in small airways, NAC prevented 
thickening of the airway wall and improved distribution of 
ventilation (Rubio et al 2000). 
Treatment with NAC in humans alters the pulmonary 
oxidant–antioxidant imbalance. NAC 600 mg/day given 
orally increased lung lavage GSH levels (Bridgeman et al 
1991), reduced O2
– production by alveolar macrophages 
(Linden et al 1988), and decreased bronchoalveolar lavage 
(BAL) polymorphonuclear leukocyte (PMN) chemilumi-
nescence in vitro (Jankowska et al 1993). NAC 600 mg/day 
in COPD patients also reduced sputum eosinophilic cation 
protein (ECP) concentrations and the adhesion of PMNs 
(Sadowska et al 2005). In vitro, NAC lowered adhesion of 
H. inﬂ  uenzae and S. pneumoniae to oropharyngeal epithelial 
cells (Riise et al 2000).
Effects on cigarette smoke-induced 
changes
Three studies have investigated the effects of NAC 600 mg/
day p.o. on parameters of inﬂ  ammation in BAL ﬂ  uid of 
“healthy” smokers (Bergstrand et al 1986; Eklund et al 1988; 
Linden et al 1988). NAC resulted in a tendency towards 
normalization of the cell composition with an increase in 
lymphocyte concentration (Linden et al 1988). In addition, 
improvements were observed in phagocytic activity of 
alveolar macrophages (Linden et al 1988) and an increase 
in the secretion of leukotriene B4 (Linden et al 1988). NAC International journal of COPD 2006:1(2)
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also reduced the stimulated production of superoxide radicals 
(Bergstrand et al 1986). Finally, markers of inﬂ  ammatory 
activity, such as eosinophil cationic protein, lactoferrin, and 
antichymotrypsin (p < 0.05) were reduced after administration 
of NAC (Eklund et al 1988).
Effects on elastase activity 
NAC treatment considerably reduced elastase activity, 
both in the bronchoalveolar cavity and in the plasma, 
which is related to its property to scavenge HOCl (Aruoma 
1989).
Modulatory effect on genes 
Redox signalling forms part of the fundamental mechanisms 
of inﬂ  ammation, such as cytokine induction, proliferation, 
apoptosis, and gene regulation for cell protection. Oxidants 
act as mediators of signal transduction, eg, activation of NF-
kb and activator protein-1 (AP-1). NAC has been shown to 
inhibit activation of NF-kb, which controls the cellular genes 
for intracellular adhesion molecules in intact cells (Schreck 
et al 1992). In addition, NAC has been shown to inhibit the 
expression of vascular cell adhesion molecule-1 in human 
endothelial cells (Marui et al 1993).
Effects on oxidative stress induced by 
viruses
Oxidant production in respiratory cells rises when they 
become infected with pathogenic viruses and this is 
accompanied by increased production of a variety of inﬂ  am-
matory mediators. NAC has been shown to have a protec-
tive role by increasing the resistance of mice to inﬂ  uenza 
virus (Streightoff et al 1966). Inﬂ  uenza virus increased 
the production of ROS in epithelial cells, and activated 
NF-kb (Knobil et al 1998). Pretreatment with NAC attenu-
ated virus-induced NF-kb and IL-8 release. Mice infected 
intranasally with inﬂ  uenza virus APR/8 showed high BAL 
levels of xanthine oxidase, TNF, and IL-6 as early as 3 days 
after infection (Akaike et al 1990). Xanthine oxidase was 
also elevated in serum and lung tissue. Administration of 
oral NAC 1 g/kg daily signiﬁ  cantly reduced the mortality 
of the infected mice (p < 0.005). Rhinoviruses also stimu-
lated increased production of H2O2 and oxidative stress of 
human respiratory epithelial cells (Biagioli et al 1999). 
Oxidative stress, in turn, caused activation of NF-kb and 
release of IL-8 and this effect was blocked by NAC in a 
dose-dependent manner.
Exhaled biomarkers of oxidative 
stress
Clinically, physicians may expect that exhaled markers 
reveal insight into the pathophysiology, have a role in the 
assessment of the severity of inﬂ  ammation–oxidative stress, 
predict lung function deterioration, and provide individual 
guidance during (pharmaco)therapy. Some biomarkers 
cannot be measured directly in exhaled air, but have to be 
measured in exhaled breath condensate (EBC), because they 
are not gaseous. The principle is to cool the exhaled air to a 
temperature around 0°C, so that the warm air condensates. 
The most common approach is to ask the subject to breathe 
tidally via a mouthpiece through a non-rebreathing valve in 
which inspiratory and expiratory air are separated. During 
expiration the exhaled air ﬂ  ows trough a condenser, which 
is cooled to 0°C by, for example, melting ice, and breath 
condensate is then collected into a collection vessel. Several 
markers can be measured in exhaled breath condensate, 
including H2O2, isoprostanes, NO metabolites, and thio-
barbituric acid-reactive substances (TBARs). 
Hydrogen peroxide
In both asthma and COPD, airway inﬂ  ammation is the 
most prominent characteristic. Activated inflammatory 
cells respond with a “respiratory burst”, which results in 
the production of ROS. Naturally occurring free radicals 
have an oxygen- or nitrogen-based unpaired electron. Clas-
sical examples are superoxide anion (O2
–), hydroxyl radical 
(OH
–), and NO. O2
– is formed from oxygen. Reaction of 
O2
– and H2O2 in the presence of transition metal produces 
OH. When catalyzed by neutrophil myeloperoxidase, H2O2 
and a chloride form HOCl. H2O2 acts as a central precursor. 
H2O2 levels reﬂ  ect the underlying state of oxidative stress in 
the lungs. The level of exhaled H2O2 signiﬁ  cantly depends 
on expiratory ﬂ  ow rate, indicating that the exhaled H2O2 is 
at least partially produced within the airways (Schleiss et al 
2000).
Methods of H2O2 measurement in breath condensate are 
based on the ability of H2O2 to react with suitable substrates 
leading to the release of colour, light, or ﬂ  uorescence. Two 
methods of analysis have been used most: the spectrophoto-
metrical method and the ﬂ  uorimetrical method. 
The concentration in normal individuals is almost 
undetectable and in many diseases the levels found are at the 
lower limit of detection of the assays employed. In COPD 
patients, the exhaled H2O2 shows a circadian rhythm and International Journal of COPD 2006:1(2) 103
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signiﬁ  cant variability over a period of one day and several 
weeks (Jeffery 2002). The concentration of H2O2 in EBC is 
increased in stable COPD patients with a further increase 
during exacerbations (Dekhuijzen et al 1996).
Increased levels of H2O2 in EBC have been shown 
in stable COPD patients, with a further increase during 
exacerbations (Dekhuijzen et al 1996). Treatment with NAC 
600
 mg once daily for 12 months reduced the concentration of 
H2O2 in EBC compared with placebo in stable COPD patients 
(FEV1 ~60%–70% of predicted) (Kasielski and Nowak 
2001). This effect was observed in the second 6 months of 
the treatment period. A higher dose of NAC (1.2
 g once daily) 
reduced the concentration of H2O2 in EBC within 30 days, 
suggesting that there is a dose-dependent effect on this marker 
of oxidative stress (De Benedetto et al 2005).
Isoprostanes
Oxygen radicals such as O2 and O2
– react with unsatu-
rated bonds of arachidonic acid, leading to the formation 
of bicycloendoperoxide intermediates. The reduction of 
these intermediates leads to the formation of isoprostanes. 
Reactive nitrogen species and polyunsaturated fatty acids 
other than arachidonic acid may also participate in the 
production of isoprostanes. Isoprostanes can be measured 
with analytic techniques such as high pressure liquid 
chromatography, gas chromatography–mass spectrometry 
or radio-immunoassay. They are stable in isolated samples 
of body ﬂ  uids and their measured values do not exhibit 
diurnal variations.
Montuschi and co-workers (Montuschi et al 2000) showed 
signiﬁ  cantly higher 8-isoprostane levels in COPD patients 
than in healthy subjects and found no difference between 
current smokers and ex-smokers, indicating that in COPD, 
exhaled 8-isoprostane is derived largely from oxidative stress 
from airway inﬂ  ammation rather than from cigarette smok-
ing. There was no relation between 8-isoprostane and age, 
sex, FEV1, and history of smoking.
NO metabolites
NO is a highly reactive molecule with a relatively short 
half-life in vivo. It can be oxidized or complexed with 
other biomolecules. The stable oxidation end products of 
NO metabolism are nitrite (NO2
–) and nitrate (NO3
–). NO 
can undergo a reaction with superoxide anion (O2
–) to form 
peroxynitrite (ONOO
–). Peroxynitrite reacts with tyrosine 
residues in proteins to form the stable product nitrotyrosine. 
NO and NO metabolites can also react with thiols (the major 
enzymatic antioxidants) to produce S-nitrosothiols. The 
concentration of nitrite can be assessed by a ﬂ  uorimetric 
assay. Incubation of samples with nitrate reductase allows 
the nitrate to be converted to nitrite, which can be measured 
subsequently. 
Recently, Corradi and co-workers compared nitrosothiols 
levels in EBC of healthy subjects (smoker and nonsmokers), 
asthma patients (mild and severe), COPD patients, and pa-
tients with CF (Corradi et al 2001). Levels of nitrosothiols 
were elevated in COPD patients compared with nonsmoking 
controls.
TBARs
TBARs are also a product of lipid peroxidation; they are 
volatile and may be present in expired breath. They are low-
molecular-weight compounds formed by the decomposition 
of certain primary and secondary lipid peroxidation products. 
At a low pH and elevated temperature, the lipid peroxidation 
products participate in a nucleophilic addition reaction with 
thiobarbituric acid, generating a red ﬂ  uorescent complex. 
They can be measured colorimetrically or ﬂ  uorimetrically.
In a cross-sectional study the concentration of TBARs 
was elevated in stable COPD patients compared with healthy 
subjects. TBARs and H2O2 concentration were elevated in 
asthma patients compared with both healthy control subjects 
and COPD patients. A signiﬁ  cant positive correlation was 
found between H2O2 concentration and TBARs concentration 
(Nowak et al 1999).
Effects of NAC on lung function and 
exacerbations
Lung function
In an open, observational survey in Sweden, the decline in 
FEV1 in COPD patients who took NAC for 2 years was less 
than in a reference group on usual care (Lundbäck et al 1992). 
This favorable effect was particularly apparent in COPD pa-
tients over 50 years of age (yearly decline of 30 mL in FEV1) 
compared with the reference group (yearly decline of 54 mL 
in FEV1). After 5 years, the loss of FEV1 in the NAC group 
was less than in the reference group (Lundbäck B 1993, pers 
comm). Clearly, it should be noted that the nature of the study 
design precludes ﬁ  rm conclusions on the effect of NAC on 
lung function decline in COPD.
Recently, the Bronchitis Randomized on NAC Cost-
Utility Study (BRONCUS) trial was conducted, testing the International journal of COPD 2006:1(2)
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hypothesis that treatment with the antioxidant NAC would 
reduce the rate of lung function decline, reduce yearly exac-
erbation rate, and improve outcome variables (Decramer et al 
2005). Patients with COPD (n = 523) were randomized in a 
multicenter, placebo-controlled study of NAC administered 
orally in a dose of 600 mg once daily. Patients were followed 
for 3 years. The rate of decline in FEV1 or vital capacity (VC) 
was not different in the 256 patients in the NAC group and 
the 267 patients in the placebo group. Secondary analysis 
in patients completing the trial showed that after 3 years, 
functional residual capacity (FRC) was decreased (– 0·374 L) 
in the NAC group, while it was slightly increased (+ 0·008 L) 
in the placebo group (p = 0·008).
Exacerbations
In a recent systematic review by Stey et al (2000), data on 
prevention of exacerbation, improvement of symptoms, 
and adverse effects were extracted from original reports 
(Figure 1). The relative beneﬁ  t and number-needed-to-treat 
were calculated for both individual trials and combined data. 
In 9 studies, 351 of 723 (48.5%) patients receiving NAC had 
no exacerbation compared with 229 of 733 (31.2%) patients 
receiving placebo: relative beneﬁ  t 1.56 (95% conﬁ  dence 
interval [CI] 1.37–1.77), number-needed-to-treat 5.8 (95% 
CI 4.5–8.1). There was no evidence of any effect of study 
period (12–24 weeks) or cumulative dose of NAC on efﬁ  cacy. 
In 5 trials, 286 of 466 (61.4%) patients receiving NAC 
reported improvement of their symptoms compared with 160 
of 462 (34.6%) patients receiving placebo: relative beneﬁ  t 
1.78 (95% CI 1.54–2.05), number-needed-to-treat 3.7 (95% 
CI 3.0–4.9). These ﬁ  ndings are in line with the outcomes of 
two previous meta-analyses using a less precise selection 
of these studies (Grandjean et al 2000; Poole and Black 
2001) and conﬁ  rm that NAC has a clinically signiﬁ  cant 
effect on the number and impact of exacerbations. Again, 
it should be stressed that patients included in these studies 
were not characterised as detailed, as currently would be 
demanded according to, eg, the GOLD guidelines (Pauwels 
et al 2001).
In the abovementioned BRONCUS trial, NAC did not 
inﬂ  uence the yearly exacerbation rate, but the hazard ratio for 
an exacerbation decreased signiﬁ  cantly by 22% in patients 
treated with NAC and not taking inhaled corticosteroids 
(p = 0·040) (Decramer et al 2005).
These effects may be explained in part by the protective 
effect of NAC on viral infections. The effects of NAC on 
inﬂ  uenza and inﬂ  uenza-like episodes have been studied 
in 262 patients suffering from nonrespiratory chronic 
degenerative diseases (De Flora et al 1997). Compared with 
placebo, NAC 600 mg twice daily for 6 months signiﬁ  cantly 
decreased both the frequency and severity of inﬂ  uenza-like 
episodes. Local and systemic symptoms were also signiﬁ  -
cantly reduced in the group receiving NAC. Although the 
seroconversion towards inﬂ  uenza virus was similar in the 
two groups, only 25% of the virus-infected subjects treated 
with NAC developed the symptomatic form of the condition 
compared with 79% of the placebo group.
Is NAC 600 mg once daily the right 
dose in patients with COPD?
It may be questioned if NAC 600 mg once daily is the right 
dose for an optimal effect in patients with COPD. The 
abovementioned studies on exhaled biomarkers indicate 
that NAC in a dose of 1200 mg daily is superior in reducing 
oxidative stress, measured by the concentration of exhaled 
H2O2. A recent study compared NAC 1200 mg daily, 600 mg 
daily, and placebo on markers of systemic inﬂ  ammation and 
symptoms in patients with COPD GOLD II-III (Zuin et al 
2005). NAC 1200 mg daily signiﬁ  cantly reduced C-reactive 
protein and IL-8 levels compared with NAC 600 mg daily 
and placebo. Both dosages were well tolerated.
Another indication that NAC in a higher dose might 
be more effective is provided by the recent data on the 
IFIGENIA study in patients with idiopathic pulmonary 
ﬁ  brosis (IPF) (Demedts et al 2005). This was a phase III, 
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Figure 1 Absence of any exacerbation with oral N-acetylcysteine (NAC) or 
placebo (P) in patients with COPD and/or chronic bronchitis. Each symbol 
represents one trial. Symbol sizes are proportional to trial sizes. Arrows are 
weighted means. -------- = line of equality. Source: Stey et al. 2000. The effect 
of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. 
Eur Respir J, 16:253–62. Copyright © 2000. Reproduced with permission of the 
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double-blind, randomised, placebo-controlled study that 
assessed the effectiveness over 1 year of high-dose NAC 
(1800 mg daily) on top of the recommended standard therapy 
of prednisone–azathioprine in 155 IPF patients. The IPF diag-
nosis was conﬁ  rmed by independent histology and radiology 
expert committees.
This study showed that NAC, on top of prednisone–
azathioprine, had a signiﬁ  cant and clinically relevant effect on 
VC and diffusion capacity (DLCO test) at 6 and 12 months. 
NAC was well tolerated and no differences in side-effects 
were observed between the two groups.
Conclusions
Oxidative stress is considered to be an important part of the 
inﬂ  ammatory response to both environmental and internal 
signals. Transcription factors like NF-kb and AP-1 are acti-
vated by oxidative stress and in turn amplify the inﬂ  ammatory 
response to noxious stimuli. In this way, both oxidative stress 
and inﬂ  ammation are involved in the complex pathophysiol-
ogy of COPD, both in terms of pathogenesis and progression 
of the disease.
In vitro and in vivo data show that NAC protects the 
lungs against toxic agents by increasing pulmonary defence 
mechanisms through its direct antioxidant properties and 
its indirect role as a precursor of GSH synthesis. Indeed, 
reductions in exhaled biomarkers like H2O2 by NAC have 
been demonstrated in intervention studies with NAC.
In patients with COPD, treatment with NAC in a dose 
of 600 mg once daily reduces the risk of exacerbations and 
improves symptoms compared with placebo. The BRONCUS 
trial showed that this is especially the case in those COPD 
patients not using inhaled corticosteroids.
The partial activity of NAC in the BRONCUS trial might 
be explained by the relatively low dose administered (ie, 
600 mg once daily). Data on exhaled biomarkers and markers 
of systemic inﬂ  ammation, as well as the recent IFIGENIA 
study, indicate that higher dosages such as 600 mg twice daily 
should be administered in patients with COPD.
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